StockNews.com Initiates Coverage on Acorda Therapeutics (NASDAQ:ACOR)

StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACORGet Rating) in a research report issued on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Shares of NASDAQ ACOR opened at $1.51 on Tuesday. The firm has a market cap of $20.01 million, a P/E ratio of -0.15 and a beta of 0.39. The company has a current ratio of 1.89, a quick ratio of 1.55 and a debt-to-equity ratio of 1.18. Acorda Therapeutics has a 1-year low of $1.50 and a 1-year high of $6.36. The business’s 50 day moving average is $1.84 and its 200-day moving average is $2.59.

Large investors have recently modified their holdings of the stock. Millennium Management LLC boosted its holdings in shares of Acorda Therapeutics by 123.4% in the 4th quarter. Millennium Management LLC now owns 90,962 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 50,241 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Acorda Therapeutics by 22.3% in the 4th quarter. Acadian Asset Management LLC now owns 467,739 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 85,335 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Acorda Therapeutics by 56.5% in the 4th quarter. Bank of America Corp DE now owns 30,402 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 10,975 shares in the last quarter. Two Sigma Advisers LP acquired a new stake in shares of Acorda Therapeutics in the 3rd quarter valued at $55,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Acorda Therapeutics during the 3rd quarter valued at $50,000. 28.55% of the stock is currently owned by institutional investors and hedge funds.

Acorda Therapeutics Company Profile (Get Rating)

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.

See Also

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.